New Drug Baxdrostat Shows Promise for Treatment-Resistant High Blood Pressure
Novel medication lowers stubborn blood pressure by 5% and reduces kidney damage markers by 55% in patients with chronic kidney disease.
Summary
A new medication called baxdrostat offers hope for people whose blood pressure remains dangerously high despite taking standard medications. In a Phase 2 clinical trial, adding baxdrostat to existing treatments lowered systolic blood pressure by about 5% in patients with chronic kidney disease and uncontrolled hypertension. The drug works by blocking aldosterone, a hormone that causes sodium and water retention, leading to elevated blood pressure and kidney damage over time. Remarkably, baxdrostat also reduced albumin loss in urine by 55%, suggesting it may protect kidney function and slow disease progression. This dual benefit could be particularly valuable for the millions of people with chronic kidney disease, who often struggle with treatment-resistant hypertension.
Detailed Summary
Baxdrostat, a novel blood pressure medication, has shown promising results for people with treatment-resistant hypertension and chronic kidney disease. The drug targets aldosterone, a hormone produced by the adrenal glands that causes the body to retain sodium and water, ultimately raising blood pressure and damaging organs over time.
In the FigHTN Phase 2 clinical trial, researchers tested baxdrostat in patients whose blood pressure remained uncontrolled despite taking ACE inhibitors or ARBs, standard first-line treatments. Participants had an average systolic blood pressure of 151 mmHg at the study's start. Adding baxdrostat to their existing medications reduced systolic pressure by approximately 5%, a clinically meaningful improvement for this difficult-to-treat population.
Perhaps more significantly, baxdrostat reduced albumin loss in urine by 55% compared to placebo. Albumin spillage into urine indicates kidney damage and predicts cardiovascular risk, so this reduction suggests the drug may protect both kidney and heart health simultaneously.
This dual benefit addresses a dangerous cycle where high blood pressure worsens kidney function, and declining kidney function further elevates blood pressure. For the millions of Americans with chronic kidney disease, current treatment options often fall short of controlling blood pressure adequately.
While these Phase 2 results are encouraging, larger Phase 3 trials will be needed to confirm baxdrostat's long-term safety and effectiveness before it becomes available to patients. The research was presented at the American Heart Association's Hypertension Scientific Sessions and published simultaneously in the Journal of the American Society of Nephrology.
Key Findings
- Baxdrostat reduced systolic blood pressure by 5% in treatment-resistant hypertension patients
- Drug decreased kidney damage marker albumin by 55% compared to placebo
- Medication works by blocking aldosterone hormone that causes sodium retention
- Treatment showed dual benefits for both blood pressure control and kidney protection
- Study focused on patients with chronic kidney disease and uncontrolled hypertension
Methodology
This is a news report summarizing results from the FigHTN Phase 2 clinical trial presented at the American Heart Association's Hypertension Scientific Sessions 2025. The source is credible, coming from the American Heart Association and simultaneously published in the Journal of the American Society of Nephrology.
Study Limitations
This is a Phase 2 trial with preliminary results, and the article appears incomplete, cutting off mid-sentence. Larger Phase 3 trials will be needed to confirm long-term safety and efficacy before clinical availability. Specific patient numbers and detailed methodology are not provided in this summary.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.